Dr. Shah on Results of ZUMA-3 Study for ALL

Video

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.

Bijal Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Currently, 5-year survival rates for patients with ALL are in the range of 5% to 10%, according to Shah. There is an unmet need for additional novel therapies, which led to the introduction of KTE-X19. The therapy is unique because physicians will sort the leukemia cells out, pulling only the T-cells into the manufacturing.

Thus far, the ZUMA-3 trial has treated 45 patients with relapsed/refractory ALL with KTE-X19. Thirty patients (66%) had ≥3 prior therapies. Of the overall 45 patients, 6, 23, and 16 patients received 2, 1, and 0.5 × 106 cells/kg, respectively. All 41 patients who had ≥2 months of follow-up, the overall response rate was 68%. Of 19 pts with ≥2 of follow-up who were treated with 1 × 106 cells/kg, the complete response (CR) or CR with incomplete hematology recovery rate was 84% and the median event-free survival was 15 months.

Related Videos
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Michael Kelly, PhD
© 2024 MJH Life Sciences

All rights reserved.